773134-11-5

Usage

Chemical Properties

Off-white powder

Upstream product

• 67-56-1 methanol 
• 183065-68-1 4-bromo-2,6-difluorobenzoic acid 
• 74-88-4 methyl iodide 
• 77-78-1 dimethyl sulfate 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 461-96-1 3,5-difluorobromobenzene 
• 497181-19-8 2,6-difluoro-4-bromobenzoyl chloride 

Downstream Products

• 957346-35-9 methyl 4-bromo-2-fluoro-6-nitromethylbenzoate 
• 948306-14-7 methyl 4-(2-cyclopropylethynyl)-2,6-difluorobenzoate 
• 908248-05-5 Methyl 2,6-difluoro-4-(3,3-dimethylbut-1-ynyl)benzoate 
• 1193162-18-3 methyl 4-bromo-2-fluoro-6-hydroxybenzoate 
• 1252554-92-9 methyl 2-[(2-aminophenyl)thio]-4-bromo-6-fluorobenzoate 
• 1160683-37-3 methyl 4-bromo-2,6-difluoro-3-nitro-benzoate 
• 1321613-00-6 2,6-difluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid methyl ester 
• 1427415-25-5 methyl 4-bromo-2-fluoro-6-methoxybenzoate 
• 1400276-61-0 p-BrPhOH 
• 1400276-62-1 p-BrPhOH 
• 1400276-63-2 p-BrPhOH 
• 957346-37-1 5-bromo-7-fluoro-2,3-dihydro-1H-isoindol-1-one 
• 1569023-16-0 C₉H₉BrFNO₂ 
• 129589-63-5 methyl 4-((tert-butyloxycarbonyl)amino)-2,6-difluorobenzoate 

Relevant academic research and scientific papers

Single-Crystalline UiO-67-Type Porous Network Stable to Boiling Water, Solvent Loss, and Oxidation

With methylthio groups flanking the carboxyl groups, the 3,3′,5,5′-tetrakis(methylthio)biphenyl dicarboxylate (TMBPD) linker forms a zirconium(IV) carboxylate porous framework featuring the topology of the UiO-67 prototype, i.e., with a face-centered-cubic array of the Zr6O4(OH)4 clusters. Thioether functionalization proves valuable because the ZrTMBPD crystal is found to be exceptionally stable not only upon long-term exposure to air but also in boiling water and a broad range of pH conditions. The hydrophobicity of the metal-organic framework can also be tuned by simple H2O2 oxidation, as illustrated in the water contact-angle measurement of the pristine and H2O2-treated ZrTMBPD solid.

3-HYDROXY-IMIDAZOLIDIN-4-ONE COMPOUNDS AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE

The invention relates to a compound of Formula (I) : Formula (I), or pharmaceutically acceptable enantiomers, or salts thereof. The present invention also relates to the use of compounds of Formula (I) as selective inhibitors of indoleamine 2,3-dioxygenas

HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS

The invention relates to activators of FXR useful in the treatment of autoimmune disorders, liver disease, intestinal disease, kidney disease, cancer, and other diseases in which FXR plays a role, having the Formula (I): (I), wherein L1, A, X1, X2, R1, R2, and R3 are described herein.

BIARYL DERIVATIVE AS GPR120 AGONIST

The present invention relates to a biaryl derivative expressed by the chemical formula 1, a method for producing the biaryl derivative, a pharmaceutical composition comprising same, and use of same, the biaryl derivative expressed by the chemical formula 1, as a GPR120 agonist, promoting GLP-1 generation in the gastro-intestinal tract, reducing insulin resistance in the liver, muscles and the like from anti-inflammatory activity in the macrophage, pancreatic cells and the like, and allowing effective use in prevention or treatment of inflammation or metabolic diseases such as diabetes, complications from diabetes, obesity, non-alcoholic fatty liver disease, fatty liver disease, and osteoporosis.

INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE

The invention relates to a compound of Formula (I), or pharmaceutically acceptable enantiomers, or salts thereof. The present invention also relates to the use of compounds of Formula (I) as selective inhibitors of indoleamine 2,3-dioxygenase. The inventi

Aminoheteroaryl benzamides as kinase inhibitors

The present invention provides a compound of Formula (I) or a salt thereof; and therapeutic uses of these compounds. The present invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds with a therapeutic co-agent.

SULFONAMIDE DERIVATIVE AND MEDICINAL USE THEREOF

Provided are sulfonamide derivatives of a specific chemical structure in which a sulfonamide group having, as a substituent, a phenyl group or a heterocyclic group having a hetero atom(s) as a constituent element(s) is present at its terminal, and pharmaceutically acceptable salts thereof. These compounds are novel compounds having excellent α4 integrin-inhibitory action.

HIGHLY SELECTIVE C-MET INHIBITORS AS ANTICANCER AGENTS

Disclosed are novel nitrogen-containing, heterocyclic, c-Met inhibitor compounds, processes for their preparation and formulations thereof. The compounds are useful as therapeutical agents for the inhibition, regulation, and control of c-Met kinase signal pathway, and useful for treating in a subject a cell proliferative disorder or disorders mediated by c-Met.

PIPERIDINE DERIVATIVES USEFUL AS GPR119 AGONISTS

Substituted piperidine compounds and pharmaceutically acceptable salts thereof are disclosed. Pharmaceutical compositions and methods of treatment are also included. The present invention relates to G-protein coupled receptor agonists. In particular, the present invention is directed to agonists of GPR 119 that are useful for the treatment of diabetes, especially type 2 diabetes, obesity, the metabolic syndrome and related diseases and conditions.

TETRACYCLIC XANTHENE DERIVATIVES AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES

The present invention discloses tetracyclic xanthene derivatives of Formula (I) and pharmaceutically acceptable salts thereof, wherein A, Y1, Y2, Z, Ra, Rb, R1a, R1b, and R2 are as defined herein. The present invention also discloses compositions comprising at least one tetracyclic xanthene derivative, and methods of using the tetracyclic xanthene derivatives for treating or preventing HCV infection in a patient.